NCT04569435View on ClinicalTrials.gov

Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

January 15, 2021

Primary Completion Date

January 10, 2024

Study Completion Date

April 23, 2024

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

ANX005

IV Infusion

Trial Locations (8)

32608

Annexon Investigational Site 02, Gainesville

33612

Annexon Investigational Site 03, Tampa

85013

Annexon Investigational Site 04, Phoenix

9492868

Annexon Investigational Site 01, Orange

T6G 2R7

Annexon Investigational Site 10, Edmonton

M4N 3M5

Annexon Investigational Site 09, Toronto

H2X 0A9

Annexon Investigational Site 07, Montreal

H3A 2B4

Annexon Investigational Site 08, Montreal

All Listed Sponsors
lead

Annexon, Inc.

INDUSTRY

NCT04569435 - Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS) | Biotech Hunter | Biotech Hunter